Pfizer (NYSE:PFE) and Flynn Pharma have appealed the record $107 million (£84.2 million) and $6.5 million (£5.2 million) fines imposed by the U.K. Competition & Markets Authority in December for the companies’ massive price hikes to their unbranded versions of anti-epilepsy drug Epanutin. In its appeal, Pfizer claims that the regulator did not consider market realities when […]
Flynn Pharma
UK slaps Pfizer with record $107m fine over price hikes
The U.K.’s Competition & Markets Authority reportedly fined Pfizer (NYSE:PFE) and Flynn Pharma a record amount for the companies’ massive price hikes to their unbranded versions of anti-epilepsy drug Epanutin. The British anti-trust watchdog fined Pfizer and Flynn Pharma $107 million (£84.2 million) and $6.5 million (£5.2 million), respectively. New York City-based Pfizer used to market the phenytoin sodium anti-epilepsy […]
